June 10, 2009 Cannasat Therapeutics Prices Offering of Units Read More >		May 25, 2009 Cannasat Therapeutics Announces Favourable Decision from United States Patent and Trademark Office Read More >
		May 19, 2009 Cannasat Therapeutics Files Preliminary Short Form Prospectus Read More >		May 15, 2009 Cannasat Therapeutics names Nathan Bryson Chief Scientific Officer Read More >
		April 14, 2009 Cannasat and IntelGenx Announce Positive Phase 1(b) Results: Improved buccal tablet outperforms oral dronabinol Read More >		March 3, 2009 Cannasat Therapeutics Announces Closing of Private Placement Read More >
				Press Release Archive

Founded in 2004, Cannasat is a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia. Cannasat currently has two new drugs in its pipeline: Relivar and Modulyn. Relivar is currently in Phase I clinical trials and Modulyn is scheduled to begin Phase I trials in 2009.